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What is the most significant result of this study? {#open201800095-sec-0001}
==================================================

![](OPEN-7-490-g002.jpg "image")That we can design and synthesize glycoporphyrin‐based compounds suitable as theranostics by combining the advantageous properties of different molecular scaffolds. Conjugation of a fluorinated glucose analogue, in contrast to its non‐fluorinated counterpart, to the porphyrin scaffold significantly increased the cellular uptake in cancerous cells. Moreover, the inherent fluorescence of the porphyrin and incorporation of fluorine, making the compounds act as ^18^F positron emission tomography tracers, add up to suitable diagnostic qualities with different imaging modalities.

What new scientific questions/problems does this work raise? {#open201800095-sec-0002}
============================================================

Several new questions can be asked. For instance, 1) what is the selectivity of the fluoro‐glycosylated porphyrins in a greater variety of cancer cell types, apart from melanoma? 2) What is the actual cytotoxic effect that can be achieved using photodynamic therapy, and how does it compare to more conventional photosensitizers? 3) How do the fluoro‐glycosylated porphyrins behave in an in vivo model, and can this be determined with the corresponding PET tracer? 4) Can the porphyrin scaffold be equipped with other carbohydrates to achieve selectivity towards variable biological targets?

What future opportunities do you see (in the light of the results presented in this paper)? {#open201800095-sec-0003}
===========================================================================================

We foresee that fluoro‐glycoporphyrins can be highly useful therapeutics in photodynamic therapy, owing to their superior properties of cellular uptake and accumulation in cancer cells. In addition, by incorporating the radioactive fluorine‐18 into the FDG moiety, a PET radiotracer can be obtained, which allows for simultaneous cancer diagnosis in clinic.

Is your current research mainly driven by curiosity or rather applied? {#open201800095-sec-0004}
======================================================================

Our research is focused on possible diagnostic applications for the compounds that we develop. We are equally interested in how to efficiently synthesize novel compounds and to evaluate their behavior in biological settings. The curiosity and challenge to see how we can design and synthesize organic compound with specific properties in order to study and eventually effect disease related processes, for example, in cancer, is the driving force in our laboratory work. ![](OPEN-7-490-g001.jpg "image")
